Shares of Avantium (AS:AVTX) moved lower on Friday after research house Kepler Cheuvreux revised its outlook on the Dutch chemicals developer. Kepler downgraded Avantium from "hold" to "reduce" and trimmed its price target to €5 from €6.40, citing an unexpectedly rapid cash outflow and an elevated risk of dilution for current shareholders.
On the day the stock fell 3.9% to €5.21, trading just above its 52-week low of €5.19, while the broader AEX index rose 0.2%.
Kepler's note says that despite a recent funding round, Avantium will require additional equity. The broker models a near-term capital raise of at least €55 million. Given the likely size of that transaction and the expectation that any new issuance would be priced at a discount to the market, Kepler cautioned that the new shares could materially dilute existing holders.
Beyond the immediate transaction, Kepler underlined the uncertainty surrounding the company's route to commercializing its FDCA technology - the monomer used to produce Avantium's plant-based PEF polymer. The broker warned that the company's cash consumption has outpaced earlier assumptions and that financing needs remain unclear while the firm transitions from technology development toward commercial-scale production.
Kepler anticipates that current shareholders would be expected to participate in the forthcoming capital round rather than see the company enter a deeper liquidity crisis. The research house also said additional equity issues should not be ruled out as the company progresses toward commercialization, noting that multiple financings could be necessary.
On that point, Kepler quantified a potential longer-term need of roughly €380 million of additional equity over coming years, which it said could be raised across several issues. The broker framed this as a scenario that would make the total dilution much larger than the initial €55 million assumption.
Kepler maintained that Avantium's underlying technology and the fundamental commercial opportunity for FDCA and PEF remain intact, but the broker argued that the scale and timing of financing requirements could significantly reduce the value attributable to existing shareholders. Kepler noted that its new €5 target sits about 7.7% below the €5.42 share price used in its report, and is a marked reduction from the prior €6.40 target.
The funding pressure outlined by Kepler stems from the capital intensity of moving from laboratory and pilot activities to full commercial production. Avantium has been investing heavily to scale FDCA production, and the broker's assessment highlights the cash strain associated with that transition.
Summary
Kepler cut Avantium's rating to "reduce" and lowered its target to €5, warning of accelerated cash burn and meaningful dilution risk. The broker models at least a €55 million near-term capital raise and flags the possibility of up to about €380 million in additional equity over time as the company works toward commercial FDCA production.
- Key points:
- Kepler downgraded Avantium to "reduce" and lowered its price target to €5 from €6.40.
- Broker assumes at least a €55 million capital raise; estimates potential longer-term equity needs of roughly €380 million.
- Avantium's shares fell 3.9% to €5.21, near a 52-week low, while the AEX was up 0.2%.
- Risks and uncertainties:
- Accelerating cash consumption could force dilutive equity raises, affecting investor returns - relevant to equity markets and the chemicals sector.
- Uncertainty over the timeline and economics of FDCA commercialization could require multiple financings, increasing funding risk for the company and impacting suppliers and investors tied to the industrial and polymer supply chain.
The situation leaves shareholders and market participants watching closely for financing announcements and any updates on the path to commercial FDCA output. Until new capital is secured on acceptable terms, Kepler's assessment suggests higher dilution risk and pressure on shareholder value as the company scales its technology.